Less than one in 10 people who could benefit from weight-loss injections such as Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the medications.
With over a billion individuals worldwide now classified as obese, it is urging more widespread and fairer access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The new guidelines recognises that excess weight is a long-term condition that can be treated with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant obstacles to widespread availability to the injections that can assist patients in reducing considerable body mass, explains the organization.
Skinny Jab Supply Crisis
Even in the current most optimistic scenario, the manufacturing of such drugs might only reach about 100 million people – under 10% of eligible patients, according to the health organization.
The advice urges governments and firms to expand availability, by approaches including patent sharing.
Exclusive production rights on the active ingredient – the core component of a leading brand – is set to lapse in multiple nations in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and boost satiety so users eat less.
Individuals typically begin shedding pounds after several weeks of commencing the once-weekly jabs.
Research suggests patients may put most of the weight back on within a year of discontinuing the drug, as their usual appetite resume.
Being overweight or obese elevates your risk for developing medical conditions, including diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity impacts people in every country and was responsible for millions of fatalities worldwide in 2024, per the WHO.
